These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 35910038)

  • 1. Pretransplant Evaluation and Liver Transplantation Outcome in PBC Patients.
    Mijic M; Saric I; Delija B; Lalovac M; Sobocan N; Radetic E; Martincevic D; Filipec Kanizaj T
    Can J Gastroenterol Hepatol; 2022; 2022():7831165. PubMed ID: 35910038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Status of Liver Transplantation for Primary Biliary Cholangitis.
    Aguilar MT; Carey EJ
    Clin Liver Dis; 2018 Aug; 22(3):613-624. PubMed ID: 30259857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary biliary cirrhosis in the era of liver transplantation.
    Raczyńska J; Habior A; Pączek L; Foroncewicz B; Pawełas A; Mucha K
    Ann Transplant; 2014 Sep; 19():488-93. PubMed ID: 25262831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodeoxycholic Acid Decreases Incidence of Primary Biliary Cholangitis and Biliary Complications After Liver Transplantation: A Meta-Analysis.
    Pedersen MR; Greenan G; Arora S; Murali AR; Mayo MJ
    Liver Transpl; 2021 Jun; 27(6):866-875. PubMed ID: 33185320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation.
    Montano-Loza AJ; Lytvyak E; Hirschfield G; Hansen BE; Ebadi M; Berney T; Toso C; Magini G; Villamil A; Nevens F; Van den Ende N; Pares A; Ruiz P; Terrabuio D; Trivedi PJ; Abbas N; Donato MF; Yu L; Landis C; Dumortier J; Dyson JK; van der Meer AJ; de Veer R; Pedersen M; Mayo M; Manns MP; Taubert R; Kirchner T; Belli LS; Mazzarelli C; Stirnimann G; Floreani A; Cazzagon N; Russo FP; Burra P; Zigmound U; Houri I; Carbone M; Mulinacci G; Fagiuoli S; Pratt DS; Bonder A; Schiano TD; Haydel B; Lohse A; Schramm C; Rüther D; Casu S; Verhelst X; Beretta-Piccoli BT; Robles M; Mason AL; Corpechot C;
    J Hepatol; 2024 Oct; 81(4):679-689. PubMed ID: 38821360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
    Bowlus CL; Kenney JT; Rice G; Navarro R
    J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic cholestatic diseases.
    Poupon R; Chazouillères O; Poupon RE
    J Hepatol; 2000; 32(1 Suppl):129-40. PubMed ID: 10728800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
    Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid.
    de Veer RC; Harms MH; Corpechot C; Thorburn D; Invernizzi P; Janssen HLA; Battezzati PM; Nevens F; Lindor KD; Floreani A; Ponsioen CY; Mayo MJ; Parés A; Mason AL; Kowdley KV; Trivedi PJ; Hirschfield GM; Bruns T; Dalekos GN; Gatselis NK; Verhelst X; Lammers WJ; Hansen BE; van Buuren HR; van der Meer AJ;
    Aliment Pharmacol Ther; 2022 Nov; 56(9):1408-1418. PubMed ID: 36138566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
    Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
    J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Harms MH; de Veer RC; Lammers WJ; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Trivedi PJ; Hirschfield GM; Pares A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Hansen BE; Buuren HRV; van der Meer AJ
    Gut; 2020 Aug; 69(8):1502-1509. PubMed ID: 31843787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis.
    Goet JC; Murillo Perez CF; Harms MH; Floreani A; Cazzagon N; Bruns T; Prechter F; Dalekos GN; Verhelst X; Gatselis NK; Lindor KD; Lammers WJ; Gulamhusein A; Reig A; Carbone M; Nevens F; Hirschfield GM; van der Meer AJ; van Buuren HR; Hansen BE; Parés A;
    Am J Gastroenterol; 2021 Jul; 116(7):1514-1522. PubMed ID: 33941746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis and Treatment of Primary Biliary Cholangitis].
    Kim KA
    Korean J Gastroenterol; 2023 Feb; 81(2):86-90. PubMed ID: 36824036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    Corpechot C; Chazouillères O; Belnou P; Montano-Loza AJ; Mason A; Ebadi M; Eurich D; Chopra S; Jacob D; Schramm C; Sterneck M; Bruns T; Reuken P; Rauchfuss F; Roccarina D; Thorburn D; Gerussi A; Trivedi P; Hirschfield G; McDowell P; Nevens F; Boillot O; Bosch A; Giostra E; Conti F; Poupon R; Parés A; Reig A; Donato MF; Malinverno F; Floreani A; Russo FP; Cazzagon N; Verhelst X; Goet J; Harms M; van Buuren H; Hansen B; Carrat F; Dumortier J;
    J Hepatol; 2020 Sep; 73(3):559-565. PubMed ID: 32275981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
    Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
    J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary biliary cirrhosis. Is (and how much of) the pathology preventible?
    Bar-Dayan Y; Gershwin ME; Levi Y; Amital H; Shoenfeld Y
    Immunol Res; 1998; 18(2):117-23. PubMed ID: 9844830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary biliary cirrhosis: therapeutic advances.
    Czul F; Peyton A; Levy C
    Clin Liver Dis; 2013 May; 17(2):229-42. PubMed ID: 23540499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.